Products for Research Use Only

NAQ

CAT: 0804-HY-151811Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-151811Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NAQ is a potent and selective μ opioid receptor partial agonist, with a Ki of 0.55 nM. NAQ shows selectivity for Mu opioid receptor over the δ receptor (Ki=132.50 nM) and the κ receptor (Ki=26.45 nM) . NAQ can be used for the research of opioid withdrawal or dependence[1].
UNSPSC
12352005
Target
Opioid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/naq.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC2=C(C=N1)C=CC=C2)N[C@H]3[C@@H]4[C@]56C7=C(O4)C(O)=CC=C7C[C@@H](N(CC8CC8)CC6)[C@@]5(O)CC3
Molecular Formula
C30H31N3O4
Molecular Weight
497.58
References & Citations
[1]Li G, et, al. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. J Med Chem. 2009 Mar 12;52 (5) :1416-27.|[2]Altarifi AA, et, al. Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats. Psychopharmacology (Berl) . 2015 Feb;232 (4) :815-24.|[3]P. Pagare P, et, al. Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment. ACS Pharmacol. Transl. Sci. 2022, 5, 11, 1197-1209.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
δ Opioid Receptor/DOR; κ Opioid Receptor/KOR; μ Opioid Receptor/MOR